Physician profile
Jay Orr
NPI 1730539289
$1,980.94
in general payments reported to CMS, 2019-2025
28 companies · $49.14 in 2025
The $49.14 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $436 · 2021: $1,045 · 2022: $40.91 · 2025: $49.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $49.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $49.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $424.56 | 2019-2022 | |
| Lilly USA, LLC | $225.87 | 2019-2021 | |
| Abbvie INC. | $213.73 | 2021-2022 | |
| Pfizer INC. | $133.38 | 2019-2025 | |
| Amarin Pharma, INC. | $131.74 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $104.80 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $77.85 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.53 | 2020-2021 | |
| Nevro Corp. | $60.19 | 2019-2021 | |
| Allergan, INC. | $59.74 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.16 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.94 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $47.05 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $46.62 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $38.37 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $35.09 | 2021 | |
| Glaxosmithkline, LLC. | $32.70 | 2019-2020 | |
| Medline Industries Lp | $19.86 | 2025 | |
| Mylan Specialty L.P. | $18.17 | 2019 | |
| Genentech USA, INC. | $17.62 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.58 | 2021 | |
| Grifols USA, LLC | $16.04 | 2021 | |
| Hikma Pharmaceuticals USA | $16.02 | 2021 | |
| Amgen INC. | $15.95 | 2019 | |
| Currax Pharmaceuticals LLC | $14.67 | 2021 | |
| Seqirus USA INC | $13.58 | 2021 | |
| Circassia INC. | $12.25 | 2019 | |
| Merck Sharp & Dohme LLC | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Orr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.